Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
16 janv. 2019 12h47 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other...
Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
04 déc. 2018 09h13 HE
|
Aileron Therapeutics, Inc.
Results in relapsed/refractory peripheral T-cell lymphoma (PTCL) demonstrate single-agent clinical proof-of-concept Combination therapy dose-escalation with low-dose cytarabine (Ara-C) in...
Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
27 nov. 2018 08h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Reports Third Quarter 2018 Financial Results
07 nov. 2018 16h10 HE
|
Aileron Therapeutics, Inc.
Manuel Aivado, MD, PhD, promoted to President and Chief Executive OfficerVojislav Vukovic, MD, appointed Senior Vice President, Chief Medical Officer, and Allen Annis, PhD, promoted to Senior Vice...
Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer
05 nov. 2018 16h05 HE
|
Aileron Therapeutics, Inc.
Allen Annis, PhD, promoted to Senior Vice President of Research WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of...
Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
01 nov. 2018 16h05 HE
|
Aileron Therapeutics, Inc.
Investigator-Initiated Phase 1Trial of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the...
Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
30 oct. 2018 16h05 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical stage leader in the field of stabilized, cell-permeable peptides to treat cancer and other...
Aileron Announces Poster Presentations at Two Scientific Conferences in November
19 oct. 2018 08h00 HE
|
Aileron Therapeutics, Inc.
Poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual MeetingPoster presentation at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium CAMBRIDGE,...
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
06 sept. 2018 09h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
Aileron Therapeutics Reports Second Quarter 2018 Financial Results
07 août 2018 16h15 HE
|
Aileron Therapeutics, Inc.
Preclinical in-vivo ALRN-6924 combination data with CDK4/6 inhibitors, PD-1/-L1 inhibitors, or paclitaxel (formulated as Abraxane or Taxol) all show promise in breast cancer and other cancer models...